The final results ended up challenging by uneven distribution of ApoE4 carriers involving placebo and treatment method teams, which was a result of an EMA ask for in the demo. A subgroup Examination, presented at CTAD, instructed which the cure profit was not as a result of this imbalance (Nov 2018 conference information).In February 2018, the demo